Ølstykke, Denmark, September 23, 2026 – Minerva Imaging, a scientifically driven CRO and CDMO specialized in targeted radionuclide therapies, has announced that Bill Barbo, a global CRO executive, joined as independent member of its Board of Directors on 4 September 2026.

Bill is a global CRO executive with more than three decades of leadership experience across international markets. During his career at Charles River Laboratories, he held several senior executive positions, including Executive Vice President and Chief Commercial Officer. In these roles, he built and led global commercial organizations, supported the growth of drug development services across regions, and helped translate scientific capabilities into long-term client partnerships. He currently serves as an independent executive consultant and advisor to companies in the life sciences sector.

The appointment follows Minerva Imaging’s continued growth as an integrated radiopharmaceutical CRO and CDMO supporting biotech and pharmaceutical companies from early discovery through manufacturing and clinical supply of radiopharmaceuticals. Minerva Imaging has recently expanded its facilities, capabilities, and international partnerships to meet the increasing demand for targeted radiopharmaceutical development services.

“Minerva Imaging has built a highly differentiated platform that combines scientific excellence with integrated radiopharmaceutical development capabilities. The company is exceptionally well positioned to support the next generation of targeted radiopharmaceutical programs, and I look forward to working with the board and management team as Minerva continues its growth journey”, said Bill Barbo.

Bill Barbo

Bill Barbo

“We are pleased to welcome Bill to the Board of Directors. His extensive experience as a global commercial CRO executive, supporting pharmaceutical and biotechnology companies, scaling international organizations, and building commercial excellence, will be highly valuable as Minerva continues to expand internationally and strengthen its position as a leading integrated radiopharmaceutical CRO and CDMO”, said Carsten H. Nielsen, Co-founder & CEO of Minerva Imaging.

About Minerva Imaging

Minerva Imaging is a fully integrated CRO and CDMO specialized in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services. Minerva’s competences are built on over 25 years of research within oncology and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.

Follow Minerva Imaging on LinkedIn for the latest news updates or visit www.minervaimaging.com for more information.